Q1 2025 Management View CEO Richard Daly highlighted Catalyst's strong start to 2025 with $141.4 million in total net ...

The regulator approved a drug from family-owned pharma Jacobus Pharmaceutical for children aged six to 17 years of age with Lambert-Eaton myasthenic syndrome (LEMS). LEMS is an autoimmune disorder ...

In addition, patients with myasthenia gravis, the Lambert-Eaton myasthenic syndrome, Guillain-Barre syndrome, chronic demyelinating polyneuropathy, sarcoidosis, neuro-Behcet's disease, paraneoplastic ...

The company takes pride in its lead product, Firdapse®, which treats Lambert-Eaton myasthenic syndrome (LEMS) with limited treatment options. Competing with other rare disease firms, it uses ...